Skip to content

Clinical Phenotypes of COPD Patients Between in Plateau and Plain

Clinical and Radiological Phenotypes of Patients With Stable COPD Between in Plateau and Plain

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04964076
Enrollment
104
Registered
2021-07-15
Start date
2020-11-01
Completion date
2021-12-31
Last updated
2023-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Brief summary

We aimed to collect clinical and radiological data of patients with stable COPD in plateau and plain, and compare the clinical phenotypic characteristics and imaging features of COPD patients in these two areas.

Detailed description

The purpose of this study was to investigate the clinical phenotypic characteristics and imaging features of patients with stable chronic obstructive pulmonary disease (COPD) in plateau and plain. We conducted a cross-sectional study, collecting clinical data of stable patients in plateau and plain, and comparing the clinical phenotypic characteristics and imaging features of COPD patients in these two areas.

Interventions

OTHERNo intervention

No intervention

Sponsors

Tibet Autonomous Region People's Hospital
CollaboratorOTHER
Peking University Third Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* meeting the diagnosis of COPD according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines and had definite airflow limitation with a post-bronchodilator forced expiratory volume in 1 second (FEV1) / forced vital capacity (FVC)\<0.7.

Exclusion criteria

* age \<40 years; * subjects with airway diseases other than COPD; * acute exacerbation of COPD in the past 3 months; * active tuberculosis; * cardiovascular or cerebrovascular events in the past 3 months; * cognitive dysfunction such as vascular dementia or Alzheimer's disease; * refusal to participate in this study.

Design outcomes

Primary

MeasureTime frameDescription
ExacerbationData were obtained during the interview.Frequency of exacerbations in the past year
Spirometry testingData were obtained during the interview.FEV1 %predicted, FVC %predicted, ratio of FEV1/FVC
EmphysemaWithin 3 months of the interview.The percentage of the LAA divided by total lung volumes (LAA%) was used as an index of the severity of emphysema in quantitative CT examination.
Assessment of respiratory symptomsData were obtained during the interview.COPD Assessment Test
Airway remodeling -1Within 3 months of the interview.Bronchial wall thickness (WT, mm) was used as one of the measurements for assessment of airway remodeling in quantitative CT examination.
Airway remodeling -2Within 3 months of the interview.Luminal area (LA, mm2) was used as one of the measurements for assessment of airway remodeling in quantitative CT examination.
Airway remodeling -3Within 3 months of the interview.Bronchial wall area (WA, mm2) was used as one of the measurements for assessment of airway remodeling in quantitative CT examination.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026